Brief: Sulbactam-Durlobactam Unanimously Recommended For Approval By FDA Advisory Committee
17/04/2023 21:55
April 17 (Reuters) - Innoviva Inc INVA.O :
* SULBACTAM-DURLOBACTAM UNANIMOUSLY RECOMMENDED FOR APPROVAL
BY
FDA ADVISORY COMMITTEE
* INNOVIVA INC - PRESCRIPTION DRUG USER FEE ACT (PDUFA)
TARGET
ACTION DATE OF MAY 29, 2023
Source text for Eikon: ID:nBw3zM3j6a
Further company coverage: INVA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innoviva
See all newsInnoviva, Inc. reports results for the quarter ended June 30 - Earnings Summary
Innoviva Q2 revenue rises on higher net product sales
Brief: Innoviva Q2 Royalty Revenue USD 56.334 Million
Brief: Nortiva Bio Launches To Develop Long-Acting Oral Medicines
Brief: Innoviva Q1 Royalty Revenue USD 55.167 Million